Cervical Esophageal Squamous Cell Carcinoma
Conditions
Interventions
Group B:Definitive chemoradiotherapy
Sponsors
Cancer Hospital Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with cervical esophageal squamous cell carcinoma of cT1b-4aN0-3 clinical stage before treatment (8thUICC-TNM stage). Patients with squamous cell carcinoma of the hypopharynx and squamous cell carcinoma of the upper thoracic esophagus can join this study; patients with T4b cervical esophageal cancer with cervical tracheal involvement but complete resection can join this study; 2. Patients aged 18-75 years; 3. There are no surgical contraindications in the preoperative evaluation of various organ functions; 4. The following laboratory tests have confirmed that the bone marrow, liver and kidney functions meet the requirements for participating in the study: hemoglobin >= 90 g/L; white blood cell count >= 4.0 x 10^9 /L; absolute value of granulocytes (ANC) >= 1.5 x 10^9 /L; platelet count >= 100 x 10^9 /L; total bilirubin <= 1.5 times upper limit of normal value; ALT and AST <= 2.5 times upper limit of normal value; international normalized ratio of prothrombin time <= 1.5 times upper limit of normal value, and partial thromboplastin time Within the normal range; creatinine <= 1.5 times the upper limit of normal; 5. No other history of malignant tumors, excluding patients with prostate cancer who received hormone therapy and obtained DFS for more than 5 years; 6. R0 resection is expected to be achieved; 7. Physical status ECOG: 0-2; 8. The subjects must understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Combined with a history of other malignant tumors (except those combined with squamous cell carcinoma of the hypopharynx and squamous cell carcinoma of the upper thoracic esophagus); 2. Mentally ill patients; 3. Those who already have or have bleeding disorders; 4. Other uncontrollable inoperable patients; 5. Female patients who are pregnant or breastfeeding; 6. Allergy to chemotherapy drugs paclitaxel and cisplatin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5 year overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Laryngo-esophageal dysfunction free survival, LDFS; | — |
Countries
China
Contacts
Public ContactJie He
Cancer Hospital Chinese Academy of Medical Sciences
Outcome results
None listed